Drug Reaction with Eosinophilia and Systemic Symptoms after Daclizamub Therapy
Neurol 91:e359-e363, Rauer,S.,et al, 2018
Multiple Sclerosis Rebound Following Herpes Zoster Infection and Suspension of Fingolimod
Neurol 79:2006-2007,1942, Gross, C.M.,et al, 2012
Primary Central Nervous System Lymphoma in a Patient Treated with Natalizumab
Ann Neurol 69:1060-1062, Phan-Ba, R.,et al, 2011
Primary Central Nervous System Lymphoma in a Patient Treated with Natalizumab
Ann Neurol 66:403-406, 261, 262, Schweikert,A.,et al, 2009
Intravenous Immunoglobulin in Autoimmune Neuromuscular Diseases
JAMA 291:2367-2375, Dalakas,M.C., 2004
Important Advances in Clinical Medicine
West J Med 123:128, Mosier,J.M.,et al, 1975
Infection Risks Among Patients with Multiple Sclerosis Treated with Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
JAMA Neurol 77:184-191, Luna, G.,et al, 2020
Natalizumab-Associated PML
Neurol 88:1197-1205, Schwab, N.,et al, 2017
Fulminant Central Nervous System Nocardiosis in a Patient Treated with Alemtuzumab for Relapsing-Remitting Multiple Sclerosis
JAMA Neurol 73:757-759, Penkert, H.,et al, 2016
Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
NEJM 366:1870-1880,1938, Bloomgren, G.,et al, 2012
Tumefactive Multiple Sclerosis Lesions under Fingolimod Treatment
Neurol 79:2000-2002,1942, Visser, F.,et al, 2012
Severe Relapses under Fingolimod Treatment Prescribed after Natalizumab
Neurol 79:2004-2006,1942, Centonze, D.,et al, 2012
Alemtuzumab for Multiples Sclerosis: Who and When to treat?
Lancet 380:1795-1797, 1792, Springer, T. & Kappos, L., 2012
Severe Cutaneous Candida Infection During Natalizumab Therapy in Multiple Sclerosis
Neurol 74:521-523, Gutwinski,S.,et al, 2010
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
NEJM 362:402-415, 456, Cohen,J.A.,et al, 2010
Relapse Management in Multiple Sclerosis
The Neurologist 15:1-5, Thrower,B.W., 2009
Opportunistic Infections and Other Risks with Newer Multiple Sclerosis Therapies
Ann Neurol 65:367-377, Berger,J.R. &Houff,S., 2009
Progressive Multifocal Leukoencephalopathy After Natalizumab Monotherapy
NEJM 361:1081-1087, Linda,H.,et al, 2009
Best Practice Recommendations for the Selection and Management of Patients with Multiple Sclerosis Receiving Natalizumab Therapy
Mutliple Sclerosis 15:S26-S36, Coyle,P.K.,et al, 2009
Assessment: The Use of Natalizumab (Tysabri) for the Treatment of Multiple Sclerosis (An Evidence-Based Review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Neurol 71:766-773, Goodin,D.S.,et al., 2008
Reactivation of JC Virus and Development of PML in Patients With Multiple Sclerosis
Neurol 68:985-990, Khalili,K.,et al, 2007
Natalizumab Plus Interferon Beta -1a for Relapsing Multiple Sclerosis
NEJM 354:911-923,965, Rudick,R.A.,et al, 2006
A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
NEJM 354:899-910,965, Polman,C.H.,et al, 2006
Natalizumab: Immune Effects and Implications for Therapy
Ann Neurol 59:731-732, Hauser,S.L. &Weiner, H.L., 2006
Emerging Monoclonal Antibody Therapies for Multiple Sclerosis
Neurologist 12:171-178, Cree,B., 2006
FDA Public Health advisory-Suspended Marketing of Tysabri (natalizumab)
www.fda.gov/cder/drug/advisory/natalizumab.htm.,(Feb 28), US Food and Drug Admin., 2005
Progressive Multifocal Leukoencephalopathy Complicating Treatment with Natalizumab and Interferon Beta-1a for Multiple Sclerosis
NEJM 353:369-374,414,432, Kleinschemidt-DeMasters,B.K. &Tyler,K.L., 2005
Progressive Multifocal Leukoencephalopathy in a Patient Treated with Natalizumab
NEJM 353:375-381, Langer-Gould,A.,et al, 2005
Clinical and MRI Outcome after Autologous Hematoipoietic Stem Cell Transplantation in MS
Neurol 62:282-284,168, Saiz,A.,et al, 2004
European Study on Intravenous Immunoglobulin in Multiple Sclerosis
Arch Neurol 61:1409-1412, Filippi,M.,et al, 2004
Intravenous Immunoglobulin Treatment Following the First Demyelinating Event Suggestive of Multiple Sclerosis
Archn Neurol 61:1515-1520, Achiron,A.,et al, 2004
Intravenous Immunoglobulin in Secondary Progressive Multiple Sclerosis: Randomised Placebo-Controlled Trial
Lancet 364:1149-1156, Hommes,O.R.,et al, 2004
IV Immunoglobulins as Add-on Treatment to Methylprednisolone for Acute Relapses in MS
Neurol 63:2028-2033, Sorensen,P.S.,et al, 2004
Disease Modifying Therapies in Multiple Sclerosis
Neurol 58:169-178, Goodin,D.S.,et al, 2002
Plasma Exchange for Severe Attacks of CNS: Demyelination: Predictors of Response
Neurol 58:143-146, Keegan,M.,et al, 2002
Systematic Review of Immunomodulatory Drugs for the Treatment of People with Multiple Sclerosis: Is There Good Quality Evidence on Effectiveness and Cost?
JNNP 70:574-579, Bryan,J.,et al, 2001
Clinicopath Conf,Wegener's Granulomatosis with Pachymeningeal Granulomatous Inflammation, Case 9-1999
NEJM 340:945-953, , 1999
Intravenous Immunoglobulin Treatment in Multiple Sclerosis, Effect on Relapses
Neurol 50:398-402, Achiron,A.,et al, 1998
Intravenous Immunoglobulin G Reduces MRI Activity in Relapsing Multiple Sclerosis
Neurol 50:1273-1281, Sorensen,P.S.,et al, 1998
Randomised Placebo-Controlled Trial of Monthly IVIg Therapy in Relapsing-Remitting MS
Lancet 349:589-593, 5861997., Fazekas,F.,et al, 1997
Management of Multiple Sclerosis
NEJM 337:1604-1611, Rudick,R.A.,et al, 1997
Open Controlled Therapeutic Trial of Intravenous Immune Globulin in Relapsing-Remitting Multiple Sclerosis
Arch Neurol 49:1233-1236, Achiron,A.,et al, 1992
A Referendum on Clinical Trial Research in Multiple Sclerosis:Opinion of Jekyll Island Workshop
Neurol 39:977-981, Noseworthy,J.H.,et al, 1989
Immunological Treatment for Multiple Sclerosis
Editorial, Lancet 1:699-7011989., , 1989
Double-Masked Trial of Azathioprine in Multiple Sclerosis
British and Dutch Multiple Sclerosis Azathioprine Trial Group, Lancet 2:179-1831988., , 1988
Dangers from Methylprednisolone Acetate Therapy by Intraspinal Injection
Arch Neurol 45:804-806, Nelson,D.A., 1988
Hyperbaric-Oxygen Treatment of Multiple Sclerosis
NEJM 308:181-186, Fischer,B.H.,et al, 1983
Intensive Immunosuppression in Progressive Multiple Sclerosis
NEJM 308:173-180, Hauser,S.L.,et al, 1983
Intraspinal Steroid Therapy
Neurol 31:168-171, Bernat,J.L., 1981